Editorial

The new Monograph of *Pharmaceuticals Policy and Law* dedicated to the “The Value of Pharmaceuticals” describes the key issues that have emerged concerning the importance of establishing the value associated with pharmaceutical interventions. Given the topics addressed, we believe that the papers are of interest to the general readership of Pharmaceuticals Policy and Law and may be of assistance in the future evaluation and development of health-related policy.

The purpose of this Monograph is to address the various topics surrounding the issue of value as applied to pharmaceuticals and their application to patient care. Concerns of access, cost, underutilisation, safety, comparative effectiveness, and cost-effectiveness have become increasingly critical. The disciplines of pharma-coeconomics and outcomes research contribute greatly to understanding the value that pharmaceuticals can achieve if used appropriately.

This edition of *Pharmaceuticals Policy and Law* seeks to provide an international overview of these challenges by outlining the viewpoints of key experts in the field.

It is hoped that these perspectives will enrich and contribute to the current discussions at international level. The authors affirm that a rational pharmacoeconomic policy should not be at the national, neither at the supranational, but at the transna-tional level: based on the relative similarity of countries in terms of their per capita health care spending.

We are grateful to the numerous participating authors including specialists on pharmacoeconomics theories, comparative effectiveness research, health and work productivity, pharmaco-economic and rare disease, post-marketing studies, pharma-coepidemiology, statistical methods in pharmacoeconomic analyses, etc.

*Pharmaceutical Policy and Law* wishes to thank all authors that have made this monograph possible. With our special thanks to Prof J. Lyle Bootman, Senior Vice President for Health Sciences, Dean and Professor of the University of Arizona College of Pharmacy, for promoting and coordinating this important topic and accepting the responsibility of acting as co-editor of this volume. We also thank to Prof Bootman his permanent support to Pharmaceuticals Policy and Law as a member of its Advisory Board.

We would also like to thank Dr. Skrepnek for his special dedication in the prepa ration of this monograph.

It is an honour for us to publish a summary of Dr Bootman’s CV which gives an insight into his scientific and professional achievements and interests.

Professor J. L. Valverde
Editor-in-Chief
Pharmaceuticals Policy and Law